Barclays PLC Has $544,000 Position in Aura Biosciences, Inc. (NASDAQ:AURA)

Barclays PLC lifted its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 256.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 61,010 shares of the company’s stock after purchasing an additional 43,897 shares during the quarter. Barclays PLC owned 0.12% of Aura Biosciences worth $544,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. American Century Companies Inc. bought a new stake in shares of Aura Biosciences during the second quarter worth $119,000. SG Americas Securities LLC bought a new stake in Aura Biosciences during the 3rd quarter worth $169,000. Rhumbline Advisers grew its position in Aura Biosciences by 39.6% during the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after acquiring an additional 18,011 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Aura Biosciences by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after purchasing an additional 8,194 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Aura Biosciences by 26.3% in the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock valued at $545,000 after purchasing an additional 15,000 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Stock Up 1.3 %

AURA opened at $7.77 on Friday. Aura Biosciences, Inc. has a twelve month low of $6.63 and a twelve month high of $12.38. The company has a fifty day moving average of $8.62 and a 200-day moving average of $8.88. The stock has a market cap of $388.11 million, a PE ratio of -4.49 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.02. Sell-side analysts anticipate that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on AURA shares. BTIG Research upped their price objective on Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Friday, October 18th. Cowen restated a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. Scotiabank lifted their price target on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday, October 18th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $23.00.

Insider Buying and Selling

In other news, insider Janet Jill Hopkins sold 11,822 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.36, for a total transaction of $110,653.92. Following the completion of the sale, the insider now owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Los Pinos Elisabet De sold 9,200 shares of Aura Biosciences stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $10.74, for a total transaction of $98,808.00. Following the completion of the sale, the insider now owns 320,647 shares of the company’s stock, valued at $3,443,748.78. This represents a 2.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,575 shares of company stock valued at $215,401 over the last 90 days. Company insiders own 5.40% of the company’s stock.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.